« Back to Record
Citation APA

Stephen, C., Scheulen, M. E., Johnston, S., Mross, K., Cardoso, F., Dittrich, C., Eiermann, W., Hess, D., Morant, R., Semiglazov, V., Markus, B., Salzberg, M., Ostapenko, V., Illiger, H.-J., Behringer, D., Bardy-Bouxin, N., Boni, J., Kong, S., Cincotta, M., & Moore, L. (2005). Phase 2 Study of Temsirolimus (CCI-779), a Novel Inhibitor of mTOR, in Heavily Pretreated Patients With Locally Advanced or Metastatic Breast Cancer. Journal of clinical oncology, 23(23), 5314-5322.


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/121908

Stephen, C., Scheulen, M. E., Johnston, S., Mross, K., Cardoso, F., Dittrich, C., Eiermann, W., Hess, D., Morant, R., Semiglazov, V., Markus, B., Salzberg, M., Ostapenko, V., Illiger, H.-J., Behringer, D., Bardy-Bouxin, N., Boni, J., Kong, S., Cincotta, M., & Moore, L. (2005). Phase 2 Study of Temsirolimus (CCI-779), a Novel Inhibitor of mTOR, in Heavily Pretreated Patients With Locally Advanced or Metastatic Breast Cancer. Journal of clinical oncology, 23(23), 5314-5322.